David Martin | CEO

David Martin, CEO, TrippBio

Dr. David E. Martin is the President and CEO of TrippBio, Inc. a clinical development-stage company developing antiviral therapies for the treatment of respiratory infections.  Dr. Martin has more than 30 years of hands-on drug development experience across the spectrum of drug discovery, preclinical development, Phase I-IV clinical development, and regulatory affairs. He has been responsible for managing more than 30 discovery/early phase clinical programs in a variety of therapeutic areas: cardiovascular, inflammation, respiratory, and HIV. Dr. Martin has published more than 142 peer-reviewed, scientific publications and has 17 granted/provisional patents. He received his PharmD from the University of Southern California (USC) and completed his Residency in Clinical Pharmacy at the USC School of Pharmacy followed by a Fellowship in Drug Development at The University of North Carolina, Chapel Hill and Glaxo, Inc.


Day 2 - November 29 @ 16:30

Development of an Oral, Broad-Spectrum Antiviral Therapeutic for Respiratory Viruses

last published: 02/Jan/24 12:15 GMT

back to speakers